{"filing":{"accession_number":"0001171843-26-005580","cik":"0001628808","ticker":"PROF","company_name":"Profound Medical Corp.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"f8k_081726.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326005580/f8k_081726.htm"},"events":[{"id":28137,"run_id":25720,"accession_number":"0001171843-26-005580","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"Profound Medical announced the introduction of new Treatment Delivery Console (TDC) software for its TULSA-PRO platform, featuring real-time interventional MRI control and user interface improvements designed to increase procedural efficiency from four to potentially six procedures per day. This is a material product enhancement for a commercial-stage medical device company, but does not fit the specific operational categories (workforce reduction, material contract, regulatory milestone). The disclosure is operational and strategic in nature—a significant software upgrade to the company's flagship platform—making operational_other the most appropriate classification.","company_name":"Profound Medical Corp.","ticker":"PROF","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":29957,"accession_number":"0001171843-26-005580","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Profound Medical announced the introduction of new Treatment Delivery Console (TDC) software for its TULSA-PRO platform, featuring real-time interventional MRI control and user interface improvements designed to increase procedural efficiency from four to potentially six procedures per day. This is a material product enhancement for a commercial-stage medical device company, but does not fit the specific operational categories (workforce reduction, material contract, regulatory milestone). The disclosure is operational and strategic in nature—a significant software upgrade to the company's flagship platform—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:35:45.854393+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29957,"accession_number":"0001171843-26-005580","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Profound Medical announced the introduction of new Treatment Delivery Console (TDC) software for its TULSA-PRO platform, featuring real-time interventional MRI control and user interface improvements designed to increase procedural efficiency from four to potentially six procedures per day. This is a material product enhancement for a commercial-stage medical device company, but does not fit the specific operational categories (workforce reduction, material contract, regulatory milestone). The disclosure is operational and strategic in nature—a significant software upgrade to the company's flagship platform—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:35:45.854393+00:00","company_name":"Profound Medical Corp.","ticker":"PROF","filing_date":"2026-08-17"}]}